Company intelligence / Profile preview

ProQR Therapeutics

Ownership: Public · PRQR
Employees: ~166
Development stage: Preclinical

Overview

ProQR is advancing its Axiomer ADAR-mediated RNA editing platform and pipeline, with up to four clinical data readouts anticipated in 2025 and 2026, including topline data for their NTCP program. Their lead program AX-0810 targeting NTCP for Cholestatic diseases is on track for CTA filing in Q2 2025 with first clinical data anticipated in Q4 2025[4].

Therapeutic areas: GastroenterologyCardiovascularNeurologyRare Diseases
Modalities: RNA therapeuticsRNA editing oligonucleotides
Industry: Biotech

Drug pipeline

28 assets

sepofarsen

27 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly and CompanyRett Syndrome Research Trust

Financials

Market cap: $204.3M
Total revenue: $8.9M
Enterprise value: $100.4M

Beyond the preview

Go deeper on ProQR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProQR Therapeutics.

Explore the full profile